Managing axial bone sarcomas in childhood

References

• Arndt CA, Crist WM. Common muskoloskeletal tumors of childhood and adolescentce. E Engl J Med. 1999;341:342–352.
   PubMed Web of Science ®Google Scholar
• Picci P. Manfrini M, Fabbri N, et al. Atlas of muskuloskeletal tumors and tumorlike lesions. Springer International Publishing Switzerland; Classic osteosarcoma (chapter 34).2014;34:147–152.
   Google Scholar
• Casali PG, Bielack S, Abecassis N, et al. ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. [2018 Oct 1];29(Suppl 4):iv79–iv95.
   PubMedGoogle Scholar
• Stiller CA, Trama A, Serraino D, et al. RARECARE Working Group Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–695.
   PubMed Web of Science ®Google Scholar
• Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–718.
   PubMedGoogle Scholar
• Stiller CA, Bielack SS, Jundt G, et al. Bone tumours in European children and adolescents, 1978-1997. Report from the automated childhood Cancer Information system project. Eur J Cancer. 2006;42:2124–2135.
   PubMed Web of Science ®Google Scholar
• Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):35–47.
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Wright CM, Pearce MS, et al. stature of young people with Malignant Bone Tumors. Pediatr Blood Cancer. 2004;42(1):59–63.
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
   PubMedGoogle Scholar
• Zils K, Bielack S, Wihelm M, et al. Osteosarcoma of the mobile spine. Ann of Oncol . 2013;24(8):2190–2195. Epub 2013 Apr 23.Ann Oncol. 2013. PMID: 23613478. .
   PubMed Web of Science ®Google Scholar
• Dreghorn CR, Newman RJ, Hardy GJ. Primary tumor of the axial skeleton. Experience of the leed regional Bone Tumors Registry. Spine (Phila Pa 1976). 1990;15:137–140.
   PubMed Web of Science ®Google Scholar
• Sundaresan N, Rosen G, Huvos AG, et al. Combined treatment of osteosarcoma of the spine. Neurosurg. 1988;14:5–13.
   Google Scholar
• Schwab J, Gasbarrini A, Bandiera S, et al. Osteosarcoma of the mobile spine. Spine (Phila Pa 1976). 2012;37:E381–E386.
   PubMedGoogle Scholar
• Schoenfiled AJ, Hornicek FJ, Pedlow FX, et al. Osteosarcoma of the spine: experience in 26 patients treated at Massachusetts General Hospital. Spine (Phila Pa 1976). 2010;10:708–714.
   Web of Science ®Google Scholar
• Dekutoski MB, Clarke MJ, Rose P, et al. Osteosarcoma of the spine: prognostic variables for local recurrence and overall survival, a multicenter ambispective study. J Neurosurg Spine. 2016;25:59–68.
   PubMed Web of Science ®Google Scholar
• Kelly SP, Ashford RU, Rao AS, et al. Primary bone tumors of the spine: a 42-year survey from the Leeds Regional Bone Tumor Registry. Eur Spine J. 2007;16:405–409.
   PubMed Web of Science ®Google Scholar
• Sundaresan N, Rosen G, Boriani S, et al. Primary malignant tumors of the spine. Orthop Clin North Am. 2009;40:21–36.
   PubMed Web of Science ®Google Scholar
• Tigani D, Pignatti G, Picci P, et al. Vertebral osteosarcoma. Ital J Orthop Traumatol. 1988;14:5–13.
   PubMedGoogle Scholar
• Boriani S, Amendola L, Corghi A, et al. Ewing’s sarcoma of the mobile spine. Eur Rev Med Pharmacol Sci. 2011;15:831–839.
   PubMed Web of Science ®Google Scholar
• Arpaci E, Yetisyigit T, Seker M, et al. Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology. Med Oncol. 2013;30:469.
   PubMed Web of Science ®Google Scholar
• Bacci G, BorianiS, Balladelli A, et al. Treatment of non metastatic Ewing’s sarcoma family tumors of the spine and sacrum: the experience from a single institution. Eur Spine J. 2009;18:1091–1095.
   PubMed Web of Science ®Google Scholar
• Grubb MR, Currier BL, Pritchard DJ, et al. Primary Ewing’s sarcoma of the spine. Spine (Phila Pa 1976). 1994;19:309–313.
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532.
   PubMed Web of Science ®Google Scholar
• Ta HT, Dass CR, Choong PFM, et al. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–263.
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23:559–568.
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18:3108–3114.
   PubMed Web of Science ®Google Scholar
• Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57:549–553.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Del Prever AB, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer. 2009;52:581–584.
   PubMed Web of Science ®Google Scholar
• Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Epub 2020 May 7 Expert Rev Anticancer Ther. 2020;20(5):415–428.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Wulff B, Delling G, et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma Study Group (COSS). Med Pediatr Oncol. 1995;24:6–12.
   PubMedGoogle Scholar
• Laitinen M, Parry P, Albergo JI, et al. Outcome of pelvic bone sarcomas in children. J Ped Orthop. 2018;38(10):537–542.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine. Experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer. 2002;94:1069–1077.
   PubMed Web of Science ®Google Scholar
• Hamilton SN, Carlson R, Hasan H, et al. Long-term outcomes and complications in pediatric Ewing sarcoma. Am J Clin Oncol. 2017;40(4):423–428. Aug.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Sciubba DM, Okuno SH, Dekutoski MB, et al. Ewing and osteogenic sarcoma: evidence for multidisciplinary management. Spine (Phila Pa 1976). 2009;34(22):S58–S68.
   PubMedGoogle Scholar
• Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725–1731.
   PubMed Web of Science ®Google Scholar
• Saab R, Rao BN, Rodriguez-Galindo C, et al. Osteosarcoma of the pelvis in children and young adults: the St. Jude Children’s Research Hospital experience. Cancer. 2005;103:1468–1474.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Palmerini E, Fabbri N, et al. Osteosarcoma of the pelvis. A monoinstitutional experience in patients younger than 41 years. Tumori. 2012;98(6):702–708.
   PubMed Web of Science ®Google Scholar
• Meazza C, Luksch R, Daolio P, et al. Axial skeletal osteosarcoma: a 25 year monoinstitutional experience in children and adolescents. Med Oncol. 2014;31(4):875–880.
   PubMed Web of Science ®Google Scholar
• Feng D, Yang X, Liu T, et al. Osteosarcoma of the spine: surgical treatment and outcomes. World J of Surg Oncol. 2013;11:89–96.
   PubMed Web of Science ®Google Scholar
• Donati D, Giacomini S, Gozzi E, et al. Osteosarcoma of the pelvis. Eur J Surg Oncol. 2004;3:332–340.
   Google Scholar
• Jawad MU, Haleem AA, Scully SP. Malignant sarcoma of the pelvic bones: treatment outcomes and prognostic factors vary by histopathology. Cancer. 2011;117:1529–1541.
   PubMed Web of Science ®Google Scholar
• Grimer RJ, Carter SR, Tillman RM, et al. Osteosarcoma of the pelvis. J Bone Joint Surg [Br]. 1999;81(5):796–802.
   Google Scholar
• Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334–341.
   PubMed Web of Science ®Google Scholar
• Janinis J, McTiernan A, Driver D, et al. A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. Ann Oncol. 2002;13:1935–1944.
   PubMed Web of Science ®Google Scholar
• Boye K, Brach Del PA, M E, et al. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma. Ped Blood Cancer. 2014;61(5):840–845.
   PubMedGoogle Scholar
• Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–1161.
   PubMed Web of Science ®Google Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230.
   PubMed Web of Science ®Google Scholar
• Picci P, Bacci G, Campanacci M, et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515–1521.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival: a report from the Children’s Oncology Grou p. J Clin Oncol. 2008;26:633–638.
   PubMed Web of Science ®Google Scholar
• Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2012;118(18):4597–4605.
   PubMed Web of Science ®Google Scholar
• Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38:1218–1225.
   PubMed Web of Science ®Google Scholar
• Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histological response to preoperative chemotherapy correlates with histological subtype of the tumor. Cancer. 2003;97:3068–3075.
   PubMed Web of Science ®Google Scholar
• Sun HH, Chen XY, Cui JQ, et al. Prognostic factors to survival of patients with chondroblastic osteosarcoma. Medicine (Baltimore). 2018;97(39):e12636. Sep. ref 54
   PubMed Web of Science ®Google Scholar
• Miller BJ, Cram P, Lynch CF, et al. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am. 2013;95(13):e89. ref 55
   PubMedGoogle Scholar
• Mankin HJ, Hornicek FJ, Temple HT, et al. Malignant tumors of the pelvis: an outcome study. Clin Orthop Relat Res. 2004;425:212–217.
   Google Scholar
• ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):113–123.
   Google Scholar
• Luetke A, Meyers P, Lewis I, et al. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532.
   PubMed Web of Science ®Google Scholar
• Longhi A, Ferrari C, De Polis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423–436.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma. The Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma. Results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1988;16:2452–2458.
   Google Scholar
• Lewis IJ, Nooij MS, Whelan J, et al. Improvement in histological response but not in survival in osteosarcoma patients treated intensified chemotherapy. A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128.
   PubMed Web of Science ®Google Scholar
• Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcome for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45:2367–2375.
   PubMed Web of Science ®Google Scholar
• Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of the intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893–899.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30(17):2112–2118.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Smeland S, Whelan JS, et al. 7. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: first Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol. 2015;33(20):2279–2287.
   PubMed Web of Science ®Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–1408.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Hoekzema N, Larson DR, et al. Osteosarcoma of the pelvis: outcome analysis of surgical treatment. Clin Orthop Relat Res. 2009;467:510–518.
   PubMed Web of Science ®Google Scholar
• Yokoyama R, Beppu Y, Tobisu K, et al. A multidisciplinary approach to the treatment of malignant pelvic bone tumors: results with eight consecutive patients. J Orthop Sci. 2000;5:449–456.
   PubMedGoogle Scholar
• Picci P, Sangiorgi L, Reograff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarocma. J Clin Oncol. 1994;12:2699–2705.
   PubMed Web of Science ®Google Scholar
• Picci P, Mercuri M, Ferrari S, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21(6):1366–1373.
   PubMed Web of Science ®Google Scholar
• Kadhim M, Womer RB, Dormans JP. Surgical treatment of pelvic sarcoma in children: outcomes for twenty-six patients. Inter Orthop. 2017;41:2149–2159.
   PubMed Web of Science ®Google Scholar
• Tomita K, Kawanara N, Baba H, et al. A new surgical technique for primary malignant vertebral tumors. Spine (Phila Pa 1976). 1997;22:324.333.
   Web of Science ®Google Scholar
• Boriani S, Biagini R, De Lure F, et al. En bloc resections of bone tumors of the thoracolumbar spine. A preliminary report on 29 patients. Spine (Phila Pa 1976). 1996;21:1927–1931.
   PubMed Web of Science ®Google Scholar
• Oertel S, Blattmann RS. Radiotherapy in the treatment of primary osteosarcoma: a single center experience. Tumori. 2010;96(4):582–588.
   PubMed Web of Science ®Google Scholar
• Tinkle C, Lu J, Li Y, et al. Curative-intent radiotherapy for pediatric osteosarcoma: the St. Jude experience. Ped Blood Cancer . 2019;66(8):e27763. Epub 2019 Apr 22. .
   PubMed Web of Science ®Google Scholar
• Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117(19):4522–4530.
   PubMed Web of Science ®Google Scholar
• Frisch S, Timmermann B. The evolving role of proton beam therapy for sarcomas. Clin Oncol. 2017;29:500–506.
   PubMed Web of Science ®Google Scholar
• De Laney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radial Oncol Biol Phys. 2005;74:732–739.
   Google Scholar
• Keole S, Ashman JB, Daniels TB. Proton therapy form sarcomas. Cancer J. 2014;20:409–414.
   PubMed Web of Science ®Google Scholar
• Kamada T, Tsujii H, Yanagi T, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20(22):4466–4471.
   PubMed Web of Science ®Google Scholar
• Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–4563.
   PubMed Web of Science ®Google Scholar
• Mohamad O, Imai R, Kamada T, et al. Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Working Group for Bone and Soft Tissue Sarcoma. Oncotarget. 2018;9(33):22976–22985.
   PubMedGoogle Scholar
• Blattmann C, Oertel S, Schulz-Ertner D, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer. 2010;10:96.
   PubMed Web of Science ®Google Scholar
• Weber D, Malyapa R, Albertini F, et al. Long term outcomes of in patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol. 2016;120:169–174.
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Park L, Savelli I. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:492–498.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Woo S, Kornguth DG, et al. Multimodality treatment of osteosarcoma: radiation in high risk cohort. Pediatr Blood Cancer. 2008;50(5):976–982.
   PubMed Web of Science ®Google Scholar
• Wagner T, Kobayashi W, Dean S, et al. Combination short-course preoperative irradiation, surgical resection, and reduced-field- high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys. 2009;73(1):259–266.
   PubMed Web of Science ®Google Scholar
• Leroy R, Benahamed N, Hulstaert F, et al. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95:267–278.
   PubMed Web of Science ®Google Scholar
• Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7:104–112.
   PubMed Web of Science ®Google Scholar
• Kuijjer ML, Hogendoorn PCW, Cleton-Jansen AM. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer. 2013;133(11):2512–2521.
   PubMed Web of Science ®Google Scholar
• Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma with advanced bone and soft tissue sarcomas. Cancer. 2009;115(22):5243–5250.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–516.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107.
   PubMed Web of Science ®Google Scholar
• Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59(3):586–588.
   PubMed Web of Science ®Google Scholar
• Longhi A, Paioli A, Palmerini E, et al. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol (Madr). 2019;58(1):124–128.
   PubMed Web of Science ®Google Scholar
• Gaspar N, Sirvent FJB, Venkatramani R, et al. Phase I combination dose-finding/phase expansion cohort of lenvatinib + etoposide + ifosfamide in patients aged 2 to 25 years with relapsed/refractory osteosarcoma. Poster session presented at: ESMO Annual 2019 Sep 27 - June1; Barcelona. Meeting.
   Google Scholar
• Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2- signaling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015.
   PubMed Web of Science ®Google Scholar
• Xie L, Xu J, Sun X, et al. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: an Open Label Phase II Clinical Trial. Oncologist. 2019;24(7):542–550.
   PubMed Web of Science ®Google Scholar
• Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120–133.
   PubMed Web of Science ®Google Scholar
• Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424–1431.
   PubMed Web of Science ®Google Scholar
• Fioramonti M, Fausti V, Pantano F, et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Sci Rep. 2018;8(1):4177.
   PubMedGoogle Scholar
• Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma:current management and future approaches through collaboration, J. Clin. Oncol. 2015;33(27):3036-3046.
   Google Scholar
• Hobusch GM, Noebauer-Huhmann I, Krall C, et al. Do long term survivors of Ewing family of tumors experience low bone mineral density and increased fracture risk? Clin Orthop Relat Res. 2014;472:3471–3479.
   PubMed Web of Science ®Google Scholar
• Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:4148–4154.
   PubMed Web of Science ®Google Scholar
• Whelan J, Hackshaw A, McTiernan A, et al. Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92. Clin Sarcoma Res. 2018 Mar 30;8:6.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Spunt SL,, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future, Med. Pediatr Oncol. 2003;40(5):276–287.
   PubMedGoogle Scholar
• Ferrari S, Sundby Hall K, Luksch R, et al. Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22(5):1221–1227. May.
   PubMed Web of Science ®Google Scholar
• Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol. 1999;17:180–190.
   PubMed Web of Science ®Google Scholar
• Luksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012;23:2970–2976.
   PubMed Web of Science ®Google Scholar
• Dirksen U, Brennan B, Le Deley MC, et al. Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators.High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019;37(34):3192–3202. Dec 1;.
   PubMed Web of Science ®Google Scholar
• Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: current scenario and unmet need. World J Orthop. 2016;7:527–538.
   PubMed Web of Science ®Google Scholar
• Yu H, Ge Y, Guo L, et al. Potential approaches to the treatment of Ewing’s sarcoma. Oncotarget. 2017;8:5523–5539.
   PubMedGoogle Scholar
• Pilepich MV, Vietti TJ, Nesbit ME, et al. Ewing’s sarcoma of the vertebral column. Int J Radiat Oncol Biol Phys. 1981;7:27–31.
   PubMed Web of Science ®Google Scholar
• Marco RA, Gentry JB, Rhines LD, et al. Ewing’s sarcoma of the mobile spine. Spine (Phila Pa 1976). 2005;30:769–773.
   PubMed Web of Science ®Google Scholar
• Whitehouse GH, Griffiths GJ. Roentgenologic aspects of spinal involvement by primary and metastatic Ewing’s tumor. J Can Assoc Radiol. 1976;27:290–297.
   PubMedGoogle Scholar
• Ilaslan H, Sundaram M, Unni KK, et al. Primary Ewing’s sarcoma of the vertebral column, Skelet. Radiol. 2004;33(9):506–513.
   Web of Science ®Google Scholar
• Venkateswaran L, Rodriguez-Galindo C, Merchant TE, et al. Primary Ewing tumor of the vertebrae: clinical characteristics, prognostic factors, and outcome. Med Pediatr Oncol. 2001;37(1):30–35.
   PubMedGoogle Scholar
• Vogin G, Helfre S, Glorion C, et al. Local control and sequelae in localised Ewing tumours of the spine: a French retrospective study. Eur J Cancer. 2013;49(6):1314–1323.
   PubMed Web of Science ®Google Scholar
• Charest-Morin R, Dirks MS, Patel S, et al. Ewing Sarcoma of the spine: prognostic variables for survival and local control in surgically treated patients. Spine (Phila Pa 1976). 2018;43(9):622–629.
   PubMed Web of Science ®Google Scholar
• Indelicato DJ, Keole SR, Shahlaee AH, et al. Spinal and paraspinal Ewing tumors. Int J Radiat Oncol Biol Phys. 2010;76(5):1463–1471.
   PubMed Web of Science ®Google Scholar
• Schuck A, Ahrens S, Von Schorlemer I, et al. Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials, Int. J Radiat Oncol Biol Phys. 2005;63(5):1562–1567.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Navid F, Liu T, et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19(4):814–820.
   PubMed Web of Science ®Google Scholar
• Hesla AC, Tsagozis P, Jebsen N, et al. Improved prognosis for patients with Ewing sarcoma in the sacrum compared with the innominate bones: the Scandinavian sarcoma group experience, J. Bone Joint Surg. 2016;98(3):199–210.
   PubMed Web of Science ®Google Scholar
• Donati D, Yin J, Di Bella C, et al. Local and distant control in non-metastatic pelvic Ewing’s sarcoma patients. J Surg Oncol. 2007;96:19–25.
   PubMed Web of Science ®Google Scholar
• Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l’Enfant. J Clin Oncol. 2006;24:3997–4002.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. [2010 Jul 10];28(20):3284–3291.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–1654.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4–11.
   PubMed Web of Science ®Google Scholar
• Krasin MJ, Rodriguez-Galindo C, Davidoff AM, et al. Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatr Blood Cancer. 2004;43:229–236.
   PubMed Web of Science ®Google Scholar
• Göbel V, Jürgens H, Etspüler G, et al. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113:187–191.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828–8834.
   PubMed Web of Science ®Google Scholar
• Gupta K, Pawaskar A, Basu S, et al. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med. 2011;36:973–977.
   PubMed Web of Science ®Google Scholar
• Lerman DM, Monument MJ, McIlvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are notreliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children’s Oncology Group. Presented at the Connective Tissue Oncology Society meeting, Berlin, Germany, 2014 Oct 15-18
   Google Scholar
• Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4:1342–1353.
   PubMed Web of Science ®Google Scholar
• Kreyer J, Ranft A, Timmermann B, et al. Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. Pediatr Blood Cancer. 2018;65(12):e27384.
   PubMed Web of Science ®Google Scholar
• Wan W, Lou Y, Hu Z, et al. Factors affecting survival outcomes of patients with non metastatic Ewing’s sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center. J Neurooncol. 2017;131:313–320.
   PubMed Web of Science ®Google Scholar
• Berger M, Fagioli F, Abate M, et al. Unusual sites of Ewing sarcoma (ES): a retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG). Eur J Cancer. 2013;49(17):3658–3665. Nov.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang Y, Lu J, et al. Impact of first-line treatment on outcomes of Ewing sarcoma of the spine. Am J Cancer Res. 2018 Jul 1;8:(7)1262–1272.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Chaichana KL, Parker SL, et al. Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database. Eur Spine J. 2013;22:1375–1382.
   PubMed Web of Science ®Google Scholar
• Arshi A, Sharim J, Park DY, et al. Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine. Spine J. 2017;17(5):645–655. May.
   PubMed Web of Science ®Google Scholar
• Mohanty S, Bilimoria KY. Comparing national cancer registries: the National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. J Surg Oncol. 2014;109:629–630.
   PubMed Web of Science ®Google Scholar
• Weiss KR, Biau DJ, Bhumbra R, et al. Axial Skeletal Location Predicts Poor Outcome in Ewing’s Sarcoma: a Single Institution Experience. Sarcoma. 2011;2011:395180. Epub 2011 Nov 24.
   PubMedGoogle Scholar
• Burgert EOJ, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8:1514–1524.
   PubMed Web of Science ®Google Scholar
• Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst. 1991;83:1460–1470.
   PubMed Web of Science ®Google Scholar
• Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment-Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26:4385–4393.
   PubMed Web of Science ®Google Scholar
• Brennan B, Kirton L, Marec-Berard P, et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). Proceedings of ASCO 2020 Virtual Meeting, Chicago, Abs #11500
   Google Scholar
• Whelan J, Le Deley MC, Dirksen U, et al. Euro-E.W.I.N.G.99 and EWING-2008 Investigators. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 Sep 6;36(31):JCO2018782516.
   Web of Science ®Google Scholar
• Bölling T, Dirksen U, Ranft A, et al. Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data. Strahlenther Onkol. 2009;185(Suppl 2):21–22. Aug.
   PubMedGoogle Scholar
• Kerr DL, Dial BL, Lazarides AL, et al. Epidemiologic and survival trends in adult primary bone tumors of the spine. Spine J. 2019 Dec 19(12):1941–1949. Epub 2019 Jul 12.Spine J. 2019. PMID: 31306757.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Gao Y, Duchman KR. Does surgery or radiation provide the best overall survival in Ewing’s sarcoma? A review of the National Cancer Data Base. J Surg Oncol. 2017;116:384–390.
   PubMed Web of Science ®Google Scholar
• Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168–177.
   PubMed Web of Science ®Google Scholar
• Foulon S, Brennan B, Gaspar N, et al. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E. W I N G Group Eur J Cancer. 2016;61:128–136, Jul
   PubMed Web of Science ®Google Scholar
• Mirzaei L, Kaal SE, Schreuder HW, et al. The Neurological Compromised Spine Due to Ewing Sarcoma. What First: surgery or Chemotherapy? Therapy, Survival, and Neurological Outcome of 15 Cases With Primary Ewing Sarcoma of the Vertebral Column. Neurosurgery. 2015;77(5):718–724. Nov.
   PubMed Web of Science ®Google Scholar
• Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. 2004;42(5): 465–470. May.
   PubMed Web of Science ®Google Scholar
• Lin TA, Ludmir EB, Liao KP, et al. Relationship between treatment center case volume and survival for localized Ewing sarcoma: the role of radiotherapy timing. Pediatr Blood Cancer. 2020;2:e28685. Sep.
   Google Scholar
• Venigalla S, Nead KT, Sebro R, et al. Association between treatment at high-volume facilities and improved overall survival in soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2018;100(4):1004–1015.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327–2340.
   PubMed Web of Science ®Google Scholar
• Gruen RL, Pitt V, Green S, et al. The effect of provider case volume on cancer mortality: systematic review and meta-analysis. CA Cancer J Clin. 2009;59:192–211.
   PubMed Web of Science ®Google Scholar
• Keole S, Ashman J, Daniels T. Proton therapy for sarcoma. Cancer J. 2014;20:409–414.
   PubMed Web of Science ®Google Scholar
• Paulino A, Nguyen T, Mai W. An analysis of primary site control and late effects according to local control modality in non‐metastatic Ewing sarcoma. Pediatr Blood Cancer. 2007;48:423–429.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Valenzuela R, Inwards C, et al. Complications in long‐term survivors of Ewing sarcoma. Cancer. 2003;98:2687–2692.
   PubMed Web of Science ®Google Scholar
• Leroy R, Benahmed N, Hulstaert F, et al. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys. 2016;95:267–278.
   PubMed Web of Science ®Google Scholar
• Odei BCL, Boothe D, Keole SR, et al. A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy. Int J Part Ther. 2017;3(3):398–406.
   PubMedGoogle Scholar
• Su Z, Indelicato DJ, Mailhot RB, et al. Impact of different treatment techniques for pediatric Ewing sarcoma of the chest wall: IMRT, 3DCPT, and IMPT with/without beam aperture. J Appl Clin Med Phys. 2020;21(6): 100–107. Jun.
   PubMed Web of Science ®Google Scholar
• Rombi B, DeLaney T, MacDonald S, et al. Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82:1142–1148.
   PubMed Web of Science ®Google Scholar
• Caruso J, Shulman D, DuBois S. Secondary malignancies in patients treated for Ewing sarcoma: a systematic review. Pediatr Blood Cancer. 2019;66(11):e27938.
   PubMed Web of Science ®Google Scholar
• Paganetti H, Athar B, Moteabbed M, et al. Assessment of radiation‐ induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol. 2012;57:6047–6061.
   PubMed Web of Science ®Google Scholar
• Uezono H, Indelicato DJ, Rotondo RL, et al. Treatment Outcomes After Proton Therapy for Ewing Sarcoma of the Pelvis. Int J Radiat Oncol Biol Phys. 2020;107(5):974–981.
   PubMed Web of Science ®Google Scholar
• Kharod SM, Indelicato DJ, Rotondo RL, et al. Outcomes following proton therapy for Ewing sarcoma of the cranium and skull base. Pediatr Blood Cancer. 2020;67(2):e28080. Epub 2019 Nov 17.
   PubMed Web of Science ®Google Scholar
• Attia S, Okuno SH, Robinson SI, et al. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors. 2015;7(2):5992.
   PubMed Web of Science ®Google Scholar
• Russo I, Di Paolo V, Crocoli A, et al. A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. Front Oncol. 2020 Aug 06. doi: 10.3389/fonc.2020.01228
   Web of Science ®Google Scholar
• Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446–455.
   PubMed Web of Science ®Google Scholar
• Casanova M, Bautista F, Hewson QC, et al. Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors. Proceedings of ASCO 2020 Virtual Meeting, Chicago, Abs #10507
   Google Scholar
• Attia S, Bolejack V, Ganjoo K, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J clin oncol. 2017;35(15):11005.
   Google Scholar